High-dose AA synergizes with anti-PD1 and anti-cytotoxic T lymphocyte associated protein 4 (anti-CTL-4) in mouse models, and increases the immunogenicity of effector T cells in many cancer types, including breast, colorectal, melanoma, pancreatic cancer, and lymphoma (14, 15). Here, PDCD1 is linked to lymphoma.